S&P 500   3,371.59 (-0.05%)
DOW   27,884.71 (-0.04%)
QQQ   271.21 (-0.47%)
AAPL   454.09 (-1.29%)
MSFT   207.90 (-0.38%)
FB   259.26 (-0.78%)
GOOGL   1,504.75 (-0.78%)
AMZN   3,126.90 (-1.08%)
NVDA   461.69 (+0.87%)
CGC   17.13 (-1.10%)
BABA   253.09 (-0.25%)
TSLA   1,634.04 (+0.80%)
GE   6.63 (+0.45%)
MU   45.52 (-1.34%)
AMD   82.03 (+0.23%)
T   29.95 (+0.13%)
F   7.04 (+0.14%)
GILD   68.50 (+0.47%)
NFLX   482.13 (+0.17%)
DIS   130.59 (-0.28%)
BAC   26.33 (-0.08%)
BA   176.22 (+0.85%)
S&P 500   3,371.59 (-0.05%)
DOW   27,884.71 (-0.04%)
QQQ   271.21 (-0.47%)
AAPL   454.09 (-1.29%)
MSFT   207.90 (-0.38%)
FB   259.26 (-0.78%)
GOOGL   1,504.75 (-0.78%)
AMZN   3,126.90 (-1.08%)
NVDA   461.69 (+0.87%)
CGC   17.13 (-1.10%)
BABA   253.09 (-0.25%)
TSLA   1,634.04 (+0.80%)
GE   6.63 (+0.45%)
MU   45.52 (-1.34%)
AMD   82.03 (+0.23%)
T   29.95 (+0.13%)
F   7.04 (+0.14%)
GILD   68.50 (+0.47%)
NFLX   482.13 (+0.17%)
DIS   130.59 (-0.28%)
BAC   26.33 (-0.08%)
BA   176.22 (+0.85%)
S&P 500   3,371.59 (-0.05%)
DOW   27,884.71 (-0.04%)
QQQ   271.21 (-0.47%)
AAPL   454.09 (-1.29%)
MSFT   207.90 (-0.38%)
FB   259.26 (-0.78%)
GOOGL   1,504.75 (-0.78%)
AMZN   3,126.90 (-1.08%)
NVDA   461.69 (+0.87%)
CGC   17.13 (-1.10%)
BABA   253.09 (-0.25%)
TSLA   1,634.04 (+0.80%)
GE   6.63 (+0.45%)
MU   45.52 (-1.34%)
AMD   82.03 (+0.23%)
T   29.95 (+0.13%)
F   7.04 (+0.14%)
GILD   68.50 (+0.47%)
NFLX   482.13 (+0.17%)
DIS   130.59 (-0.28%)
BAC   26.33 (-0.08%)
BA   176.22 (+0.85%)
S&P 500   3,371.59 (-0.05%)
DOW   27,884.71 (-0.04%)
QQQ   271.21 (-0.47%)
AAPL   454.09 (-1.29%)
MSFT   207.90 (-0.38%)
FB   259.26 (-0.78%)
GOOGL   1,504.75 (-0.78%)
AMZN   3,126.90 (-1.08%)
NVDA   461.69 (+0.87%)
CGC   17.13 (-1.10%)
BABA   253.09 (-0.25%)
TSLA   1,634.04 (+0.80%)
GE   6.63 (+0.45%)
MU   45.52 (-1.34%)
AMD   82.03 (+0.23%)
T   29.95 (+0.13%)
F   7.04 (+0.14%)
GILD   68.50 (+0.47%)
NFLX   482.13 (+0.17%)
DIS   130.59 (-0.28%)
BAC   26.33 (-0.08%)
BA   176.22 (+0.85%)
Log in

LON:INDVIndivior Share Price, Forecast & News

GBX 121.60
+2.60 (+2.18 %)
(As of 08/14/2020 10:21 AM ET)
Add
Compare
Today's Range
118.40
Now: GBX 121.60
124.40
50-Day Range
75.05
MA: GBX 100.72
142.40
52-Week Range
0.77
Now: GBX 121.60
165.80
Volume1.25 million shs
Average Volume2.44 million shs
Market Capitalization£890.64 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Read More
Indivior logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.13 out of 5 stars


Industry, Sector and Symbol

Industry Drugs - Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1753-217800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£700 million
Cash FlowGBX 106.46 per share
Book ValueGBX 5.30 per share

Profitability

Miscellaneous

Employees915
Market Cap£890.64 million
Next Earnings DateN/A
OptionableNot Optionable
GBX 121.60
+2.60 (+2.18 %)
(As of 08/14/2020 10:21 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INDV News and Ratings via Email

Sign-up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Indivior (LON:INDV) Frequently Asked Questions

How has Indivior's stock price been impacted by Coronavirus?

Indivior's stock was trading at GBX 46.21 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, INDV stock has increased by 163.1% and is now trading at GBX 121.60.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Indivior?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Indivior
.

What price target have analysts set for INDV?

2 Wall Street analysts have issued 1 year price objectives for Indivior's shares. Their forecasts range from GBX 85 to GBX 200. On average, they anticipate Indivior's share price to reach GBX 142.50 in the next twelve months. This suggests a possible upside of 17.2% from the stock's current price.
View analysts' price targets for Indivior
.

Has Indivior been receiving favorable news coverage?

Media coverage about INDV stock has trended positive on Friday, InfoTrie reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Indivior earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave news stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days.
View the latest news about Indivior
.

Who are some of Indivior's key competitors?

What other stocks do shareholders of Indivior own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Indivior investors own include Bigblu Broadband (BBB), Futura Medical (FUM), Directa Plus (DCTA), Lakehouse (LAKE), Aquila Services Group (AQSG), Benchmark (BMK), Bodycote (BOY), CityFibre Infrastructure (CITY), Deltex Medical Group (DEMG) and Kingfisher (KGF).

Who are Indivior's key executives?

Indivior's management team includes the following people:
  • Mr. Shaun Thaxter, CEO & Exec. Director
  • Mr. Mark Crossley, CFO & Exec. Director
  • Dr. Christian Heidbreder, Chief Scientific Officer
  • Mr. Ingo Elfering, Chief Information & Innovation Officer
  • Mr. Jason Thompson, VP of Investor Relations

What is Indivior's stock symbol?

Indivior trades on the London Stock Exchange (LON) under the ticker symbol "INDV."

How do I buy shares of Indivior?

Shares of INDV and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Indivior's stock price today?

One share of INDV stock can currently be purchased for approximately GBX 121.60.

How big of a company is Indivior?

Indivior has a market capitalization of £890.64 million and generates £700 million in revenue each year. Indivior employs 915 workers across the globe.

What is Indivior's official website?

The official website for Indivior is indivior.com.

How can I contact Indivior?

Indivior's mailing address is 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom. The specialty pharmaceutical company can be reached via phone at +44-1753-217800.

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.